Case Report

Rosuvastatin-Induced Thrombocytopenia

Authors: Ioannis Vrettos, MD, Sotiris Papageorgiou, MD, Christina Economopoulou, MD, Vasiliki Pappa, MD, Panagiotis Tsirigotis, MD, Nikolaos Tountas, MD, Theofanis Economopoulos, MD, John Dervenoulas, MD

Abstract

Rosuvastatin, a statin indicated for patients with primary hypercholesterolemia, mixed dyslipidemia and familial hypercholesterolemia, is well tolerated by most patients. Its most common adverse effects are gastrointestinal derangement, muscle aches and hepatitis. One rare complication of statin treatment is severe thrombocytopenia. The case of a 65-year-old patient who developed severe thrombocytopenia while on rosuvastatin is presented, in addition to a review of the literature.


Key Points


* Rosuvastatin is used in patients with primary hypercholesterolemia, mixed dyslipidemia and familial hypercholesterolemia.


* Rosuvastatin is generally well tolerated.


* A rare complication of rosuvastatin is severe thrombocytopenia.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Cheng JW. Rosuvastatin in the management of hyperlipidemia. Clin Ther 2004;26:1368–1387.
 
2. Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: a look back and a look ahead. Can J Cardiol 1992;8:843–864.
 
3. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079–1082.
 
4. Shepherd J, Vidt DG, Miller E, et al. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program cardiology. Cardiology 2007;107:433–443.
 
5. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498–511.
 
6. González-Ponte ML, González-Ruiz M, Duvós E, et al. Atorvastatin-induced severe thrombocytopenia. Lancet 1998;352:1284.
 
7. Groneberg DA, Barkhuizen A, Jeha T. Simvastatin-induced thrombocytopenia. Am J Hematol2001;67:277.
 
8. Yamada T, Shinohara K, Katsuki K. Severe thrombocytopenia caused by simvastatin in which thrombocyte recovery was initiated after severe bacterial infection. Clin Drug Investig 1998;16:172–174.
 
9. Possamai G, Bovo P, Santonastaso M. Thrombocytopenic purpura during therapy with simvastatin. Haematologica 1992;77:357–358.
 
10. Ames PR. Simvastatin-induced thrombocytopaenia: a further case and a brief on its clinical relevance. Ann Hematol 2008;87:773–774.
 
11. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007;357:580–587.
 
12. Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med 2009;133:309–314.
 
13. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3–40.
 
14. George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998;129:886–890.
 
15. Nikolsky E, Sadeghi HM, Effron MB, et al. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol 2005;96:474–481.